# Comparing Ocular AEs in Next-Gen Treatments

An episode of [New Retina Radio by Eyetube](https://invisiblenetwork.ai/podcast/1177017186), 20 Aug 2026, 14 min.

Audio: https://traffic.megaphone.fm/BMCL2222389022.mp3

What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them.